These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 30315824)

  • 1. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
    Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
    Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
    Heikamp EB; Henrich JA; Perner F; Wong EM; Hatton C; Wen Y; Barwe SP; Gopalakrishnapillai A; Xu H; Uckelmann HJ; Takao S; Kazansky Y; Pikman Y; McGeehan GM; Kolb EA; Kentsis A; Armstrong SA
    Blood; 2022 Feb; 139(6):894-906. PubMed ID: 34582559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia.
    Chen Y; Anastassiadis K; Kranz A; Stewart AF; Arndt K; Waskow C; Yokoyama A; Jones K; Neff T; Lee Y; Ernst P
    Cancer Cell; 2017 Jun; 31(6):755-770.e6. PubMed ID: 28609655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
    Chen Y; Ernst P
    Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
    Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
    Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
    Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
    Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Menin critically links MLL proteins with LEDGF on cancer-associated target genes.
    Yokoyama A; Cleary ML
    Cancer Cell; 2008 Jul; 14(1):36-46. PubMed ID: 18598942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
    Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
    Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
    Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
    Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction.
    Borkin D; Klossowski S; Pollock J; Miao H; Linhares BM; Kempinska K; Jin Z; Purohit T; Wen B; He M; Sun D; Cierpicki T; Grembecka J
    J Med Chem; 2018 Jun; 61(11):4832-4850. PubMed ID: 29738674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
    Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
    J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription.
    Huang J; Gurung B; Wan B; Matkar S; Veniaminova NA; Wan K; Merchant JL; Hua X; Lei M
    Nature; 2012 Feb; 482(7386):542-6. PubMed ID: 22327296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition.
    Soto-Feliciano YM; Sánchez-Rivera FJ; Perner F; Barrows DW; Kastenhuber ER; Ho YJ; Carroll T; Xiong Y; Anand D; Soshnev AA; Gates L; Beytagh MC; Cheon D; Gu S; Liu XS; Krivtsov AV; Meneses M; de Stanchina E; Stone RM; Armstrong SA; Lowe SW; Allis CD
    Cancer Discov; 2023 Jan; 13(1):146-169. PubMed ID: 36264143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
    Borkin D; He S; Miao H; Kempinska K; Pollock J; Chase J; Purohit T; Malik B; Zhao T; Wang J; Wen B; Zong H; Jones M; Danet-Desnoyers G; Guzman ML; Talpaz M; Bixby DL; Sun D; Hess JL; Muntean AG; Maillard I; Cierpicki T; Grembecka J
    Cancer Cell; 2015 Apr; 27(4):589-602. PubMed ID: 25817203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
    Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
    Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
    Fiskus W; Boettcher S; Daver N; Mill CP; Sasaki K; Birdwell CE; Davis JA; Takahashi K; Kadia TM; DiNardo CD; Jin Q; Qi Y; Su X; McGeehan GM; Khoury JD; Ebert BL; Bhalla KN
    Blood Cancer J; 2022 Jan; 12(1):5. PubMed ID: 35017466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Menin-MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers.
    Shi Q; Xu M; Kang Z; Zhang M; Luo Y
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in
    Wang H; Shah CA; Hu L; Huang W; Platanias LC; Eklund EA
    J Biol Chem; 2020 Jul; 295(28):9663-9675. PubMed ID: 32467231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.